How to Interpret a Hepatitis B Serology Panel (Five-Item HBV Test)

Understanding hepatitis B serology—commonly referred to as the “five-item panel” or “two pairs and one”—is essential for diagnosing, staging, and managing hepatitis B virus (HBV) infection. This blood test evaluates five specific markers: hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs), hepatitis B e-antigen (HBeAg), hepatitis B e-antibody (anti-HBe), and hepatitis B core antibody (anti-HBc). Collectively, these markers provide insight into viral activity, immune response, infectivity, and disease phase.

HBsAg is the first detectable marker during acute infection and indicates active viral replication or chronic carriage if persisting beyond six months. Its presence confirms current HBV infection. Anti-HBs, in contrast, reflects immunity—either from prior vaccination or resolved infection—and is protective against reinfection. HBeAg signals high levels of viral replication and increased infectivity; its detection often correlates with elevated HBV DNA and higher risk of liver damage. Conversely, anti-HBe typically emerges after HBeAg seroconversion and suggests reduced viral replication—though exceptions exist, particularly in precore or basal core promoter mutants where HBV DNA may remain high despite anti-HBe positivity.

The IgM class of anti-HBc is a key indicator of recent or acute infection, while total (IgG + IgM) anti-HBc persists lifelong after exposure and serves as a marker of past or ongoing infection. Importantly, anti-HBc alone—without HBsAg or anti-HBs—may indicate occult HBV infection or isolated core antibody, requiring further evaluation with HBV DNA testing.

Interpretation requires clinical context: a positive HBsAg with negative anti-HBs, positive HBeAg, and positive anti-HBc (IgM or total) typically signifies acute or immune-active chronic hepatitis B. A pattern showing HBsAg+, anti-HBe+, and anti-HBc+—with low or undetectable HBV DNA—often reflects the inactive carrier state. Fully resolved infection shows anti-HBs+ and anti-HBc+, with HBsAg negative. Vaccinated individuals will have isolated anti-HBs positivity without anti-HBc.

Clinicians must integrate these serologic results with quantitative HBV DNA, liver enzyme levels (ALT/AST), liver ultrasound, and, when indicated, non-invasive fibrosis assessment or biopsy. Serial monitoring—not single-timepoint interpretation—is critical for tracking disease evolution and guiding antiviral therapy decisions.